John Winscott, MD
Interventional Cardiology · Jackson, MSNPI 1124113667
Payments from drug & device makers
Across 1,276 payments — averaging $378.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$394K
- Shockwave Medical, Inc$74K
- Abiomed$5K
- Inari Medical, Inc.$3K
- Endologix LLC$1K
- Penumbra, Inc.$830
- plus $5K from 31 others
Across 3 payments — averaging $1425.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$4K
What the payments were for
- Consulting fees$66,80514%
- Speaking & faculty fees$286,38859%
- Travel & lodging$84,80118%
- Food & beverage$44,3689%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 865 | $393,875 |
| Shockwave Medical, Inc | 91 | $74,069 |
| Abiomed | 164 | $4,907 |
| Inari Medical, Inc. | 36 | $2,690 |
| Endologix LLC | 5 | $1,149 |
| Penumbra, Inc. | 8 | $830 |
| W. L. Gore & Associates, Inc. | 2 | $591 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $522 |
| Stryker | 8 | $437 |
| Asahi Intecc USA, Inc. | 4 | $319 |
| Philips North America LLC | 6 | $302 |
| Abbott | 5 | $264 |
| Boston Scientific | 4 | $248 |
| Boehringer Ingelheim | 4 | $220 |
| Johnson & Johnson | 7 | $172 |
| Pfizer | 11 | $164 |
| Cvrx, Inc. | 1 | $146 |
| Novartis | 9 | $139 |
| Livanova USA, Inc. | 1 | $134 |
| AstraZeneca | 2 | $133 |
| Heartflow, Inc. | 1 | $121 |
| Cardiva Medical, Inc. | 6 | $114 |
| Limflow Inc. | 1 | $106 |
| Novo Nordisk | 1 | $93 |
| Scpharmaceuticals Inc. | 1 | $92 |
| Bayer | 1 | $88 |
| Amgen | 5 | $76 |
| Edwards Lifesciences | 2 | $66 |
| Innovation Technologies Inc | 2 | $64 |
| Kestra Medical Technology Services, Inc. | 1 | $45 |
| Biotronik Inc. | 2 | $40 |
| Imperative Care, Inc | 1 | $30 |
| Gilead | 2 | $30 |
| Angiodynamics, Inc. | 1 | $29 |
| Merck | 1 | $23 |
| Impulse Dynamics (USA) Inc. | 1 | $23 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HawkOne$178,241
- TurboHawk$92,776
- IN.PACT Admiral$85,082
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$72,529
- FlowMet$7,194
- Abre$3,527
- FLOWTRIEVER CATHETER, S$2,067
- CT THROMBECTOMY SYSTEM KIT$2,067
- FlowMet-R$1,506
- MO.MA ULTRA$1,050
- Torus Stent Graft System$1,018
- ENDOCROSS Device$1,018
- Impella$746
- Chocolate PTA Balloon$591
- Indigo System$581
- Product in Development$580
- CHOCOLATE PTA BALLOON CATHETER$425
- Endurant$354
- SpiderFX$316
- VenaSeal$228
How this compares
$482,361 in reported general payments places this provider in the 95th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 40 | $42,801 |
| EliquisApixaban | 35 | $34,573 |
| JardianceEmpagliflozin | 30 | $27,496 |
| FarxigaDapagliflozin Propanediol | 15 | $18,609 |
| Repatha SureclickEvolocumab | 12 | $9,543 |
| BrilintaTicagrelor | 16 | $7,533 |
| ClopidogrelClopidogrel Bisulfate | 173 | $1,656 |
| Metoprolol Succinate | 113 | $1,489 |
| Nifedipine ErNifedipine | 13 | $1,474 |
| Atorvastatin Calcium | 130 | $1,067 |
| Rosuvastatin Calcium | 115 | $896 |
| Carvedilol | 69 | $510 |
| Ezetimibe | 28 | $486 |
| Losartan Potassium | 59 | $450 |
| Nitroglycerin | 25 | $353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $139 | $42,80140 claims |
| PfizerEliquis | $164 | $34,57335 claims |
| Boehringer IngelheimJardiance | $220 | $27,49630 claims |
| AstraZenecaFarxiga, Brilinta | $133 | $26,14231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Jackson
- Brett BennettJackson$561K
- William CrowderJackson$419K
- James BennettJackson$286K
- Richard GuynesJackson$93K
- Alejandro Lemor FerrandJackson$60K
- David YoungJackson$28K
- William NicholsJackson$25K
- Catherine LoweJackson$21K
- Jeremy WhiteJackson$18K
- Kellan AshleyJackson$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.